Value-Based Cancer Care Web Exclusives


February 2019

Maintenance Therapy with Ixazomib Significantly Prolongs Progression-Free Survival Following Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: Results from the TOURMALINE-MM3 Trial

Maintenance Therapy, Multiple Myeloma

San Diego, CA—In patients with multiple myeloma (MM), the use of drug therapy as maintenance has been shown to prolong the length of time the disease is controlled. Specifically, use of maintenance therapy may affect overall survival, particularly when it is used after an autologous stem-cell transplant (ASCT). [ Read More ]